12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

• Dermata Therapeutics DRMA shares increased by 68.4% to $3.25 during Friday's pre-market session. The market value of their outstanding shares is at $2.7 million. The company's, Q1 earnings came out yesterday.
• ARS Pharmaceuticals SPRY shares moved upwards by 53.93% to $6.96. The market value of their outstanding shares is at $657.3 million.
• Athenex ATNX shares rose 20.68% to $1.4. The market value of their outstanding shares is at $12.1 million.
• ABVC BioPharma ABVC stock increased by 14.49% to $0.89. The market value of their outstanding shares is at $29.5 million.
• Babylon Holdings BBLN shares moved upwards by 14.28% to $1.36. The company's market cap stands at $33.8 million. As per the news, the Q1 earnings report came out 2 days ago.
• PhenomeX CELL shares increased by 12.19% to $0.92. The market value of their outstanding shares is at $90.8 million. The company's, Q1 earnings came out yesterday.

Losers

• Assure Hldgs IONM shares decreased by 37.3% to $1.21 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 million. As per the news, the Q1 earnings report came out 2 days ago.
• Sunshine Biopharma SBFM shares decreased by 22.23% to $0.7. The company's market cap stands at $15.8 million. As per the press release, Q1 earnings came out 2 days ago.
• Impel Pharmaceuticals IMPL shares decreased by 20.18% to $1.82. The company's market cap stands at $43.2 million. As per the news, the Q1 earnings report came out today.
• Biolase BIOL shares decreased by 16.55% to $0.2. The company's market cap stands at $5.2 million. As per the news, the Q1 earnings report came out yesterday.
• Vyant Bio VYNT stock fell 16.54% to $0.28. The company's market cap stands at $1.7 million.
• Telesis Bio TBIO stock decreased by 14.59% to $2.46. The company's market cap stands at $73.0 million. As per the news, the Q1 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.